Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy

被引:1
作者
Sharma, Parul [1 ]
Singh, Navneet [2 ]
Sharma, Siddharth [1 ,3 ]
机构
[1] Thapar Inst Engn & Technol, Dept Biotechnol, Patiala, Punjab, India
[2] Post Grad Inst Med Educ & Res, Dept Pulm Med, Chandigarh, India
[3] Thapar Inst Engn & Technol, Patiala 147004, Punjab, India
关键词
ABC transporter; lung cancer; polymorphism; risk; toxicity; MULTIDRUG-RESISTANCE PROTEINS; P-GLYCOPROTEIN EXPRESSION; ASSOCIATION ANALYSIS; POLYMORPHISMS; PHARMACOGENETICS; VARIANTS; DISPOSITION; INJURY; BCRP; MRP1;
D O I
10.1002/jbt.23269
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ATP-binding cassette (ABC) transporters are expressed in various human tissues and play a vital role in the efflux of various chemotherapeutic drugs. The current study has assessed genetic variants of ABCB1, ABCC1, ABCC2, and ABCG2 genes in 407 lung cancer patients undergoing platinum-based doublet chemotherapy. The association of ABCB1 ((CT)-T-1236, (CT)-T-3435, and G(2677)T/A), ABCC1 (G(3173)A and G(2168)A),ABCC2 (G(4544)A), and ABCG2 (C(421)A) polymorphisms with chemotherapy-induced adverse events were assessed, and statistical analysis was conducted. Our data showed that patients harboring heterozygous (GA) genotype for ABCC1 G(3173)A had an increased risk of developing leukopenia (odds ratio [OR] = 1.88, p = 0.04) and anemia (adjusted odds ratio [AOR] = 2.70, p = 0.03). For ABCC2 G(4544)A polymorphism, patients harboring one copy of the mutant (GA) allele showed an increased risk of developing anemia (OR = 4.24, p = 0.03). After adjusting with various confounding factors, the heterozygous (GA) genotype showed a 5.63-fold increased risk of developing anemia (AOR = 5.63, p = 0.03). The ABCB1 G(2677)A (OR = 0.37, p = 0.008) and ABCC1 G(3173)A (OR = 0.54, p = 0.04) polymorphism showed a lower incidence of developing nephrotoxicity. In ABCG2 C(421)A polymorphism, patients harboring heterozygous (CA) genotype had a lower incidence of having diarrhea (OR = 0.25, p = 0.04). An increased risk of having diarrhea was observed in the heterozygous genotype (GA) for ABCC1 G(3173)A polymorphism (AOR = 2.78, p = 0.04). An increased risk of liver injury was found in the patients carrying heterozygous genotype of the ABCC1 G(3173)A (OR = 2.06, p = 0.02) and ABCB1 (CT)-T-1236 (OR = 1.85, p = 0.01). This study demonstrates the role of polymorphic variations in ABCB1, ABCC1, ABCC2, and ABCG2 in predicting hematological, nephrotoxicity, gastrointestinal, and hepatotoxicity.
引用
收藏
页数:13
相关论文
共 53 条
  • [1] CHEMOSENSITISATION AND DRUG ACCUMULATION EFFECTS OF CYCLOSPORINE-A, PSC-833 AND VERAPAMIL IN HUMAN MDR LARGE CELL LUNG-CANCER CELLS EXPRESSING A 190K MEMBRANE-PROTEIN DISTINCT FROM P-GLYCOPROTEIN
    BARRAND, MA
    RHODES, T
    CENTER, MS
    TWENTYMAN, PR
    [J]. EUROPEAN JOURNAL OF CANCER, 1993, 29A (03) : 408 - 415
  • [2] Drug transporters of platinum-based anticancer agents and their clinical significance
    Burger, Herman
    Loos, Walter J.
    Eechoute, Karel
    Verweij, Jaap
    Mathijssen, Ron H. J.
    Wiemer, Erik A. C.
    [J]. DRUG RESISTANCE UPDATES, 2011, 14 (01) : 22 - 34
  • [3] Genome-wide Association Study on Platinum-induced Hepatotoxicity in Non-Small Cell Lung Cancer Patients
    Cao, Songyu
    Wang, Cheng
    Ma, Hongxia
    Yin, Rong
    Zhu, Meng
    Shen, Wei
    Dai, Juncheng
    Shu, Yongqian
    Xu, Lin
    Hu, Zhibin
    Shen, Hongbing
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [4] Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression
    Cha, Pei-Chieng
    Mushiroda, Taisei
    Zembutsu, Hitoshi
    Harada, Hiromasa
    Shinoda, Noriyuki
    Kawamoto, Shunji
    Shimoyama, Rai
    Nishidate, Toshihiko
    Furuhata, Tomohisa
    Sasaki, Kazuaki
    Hirata, Koichi
    Nakamura, Yusuke
    [J]. JOURNAL OF HUMAN GENETICS, 2009, 54 (10) : 572 - 580
  • [5] STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline
    Chaplin, Marty
    Kirkham, Jamie J.
    Dwan, Kerry
    Sloan, Derek J.
    Davies, Geraint
    Jorgensen, Andrea L.
    [J]. PLOS MEDICINE, 2020, 17 (09)
  • [6] Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients
    Chen, Songjian
    Huo, Xia
    Lin, Yi
    Ban, Hao
    Lin, Yincheng
    Li, Weiqiu
    Zhang, Bao
    Au, William W.
    Xu, Xijin
    [J]. INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH, 2010, 213 (02) : 140 - 145
  • [7] The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients
    Chew, Sin-Chi
    Singh, Onkar
    Chen, Xiangai
    Ramasamy, Rathi Devi
    Kulkarni, Tejal
    Lee, Edmund J. D.
    Tan, Eng-Huat
    Lim, Wan-Teck
    Chowbay, Balram
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1471 - 1478
  • [8] Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy
    Choi, Jung Ran
    Kim, Jeong-Oh
    Kang, Dae Ryong
    Shin, Jung-Young
    Zhang, Xiang Hua
    Oh, Ji Eun
    Park, Ji-Young
    Kim, Kyoung-Ah
    Kang, Jin-Hyoung
    [J]. CANCER RESEARCH AND TREATMENT, 2015, 47 (03): : 509 - 517
  • [9] Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
    Cortejoso, Lucia
    Garcia, Maria I.
    Garcia-Alfonso, Pilar
    Gonzalez-Haba, Eva
    Escolar, Fernando
    Sanjurjo, Maria
    Lopez-Fernandez, Luis A.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1463 - 1472
  • [10] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
    Cusatis, George
    Gregorc, Vanesa
    Li, Jing
    Spreafico, Anna
    Ingersoll, Roxann G.
    Verweij, Jaap
    Ludovini, Vienna
    Villa, Eugenio
    Hidalgo, Manuel
    Sparreboom, Alex
    Baker, Sharyn D.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (23) : 1739 - 1742